Deutsche Bank Reiterates Buy Rating on Insulet Corporation
Deutsche Bank maintains its buy rating for Insulet Corporation with a $190 price target, a 23.52% upside from the current price.
Key Points
- Deutsche Bank reiterated its buy rating on Insulet Corporation (PODD) with a $190 price target on June 23, 2026.
- Deutsche Bank's $190 price target implies 23.52% upside from Insulet Corporation's ($PODD) current $153.82 share price.
- Insulet's stock traded near $138.97 on Tuesday, with a market cap of $9.63 billion and a P/E ratio of 32.4.
- Insider transactions included both buys and sells, while analysts like Truist and Citigroup also weighed in with ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Deutsche Bank reiterated its buy rating on Insulet Corporation (NasdaqGS: PODD), setting a price target of $190. This reaffirmation comes as Insulet's shares traded around $138.97 on Tuesday.
Deutsche Bank vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
Deutsche Bank's analyst Kieran Ryan maintained the buy rating on Insulet with a $190 price target. Earlier, Truist Securities also maintained a buy rating with a $219 target on June 12, 2026. Citigroup kept a hold rating with a $165 target on May 28, 2026. Other firms like BTIG, B of A Securities, and Canaccord Genuity have also maintained buy ratings with targets ranging from $208 to $249.
Other Institutional Activity in Insulet Corporation
In recent institutional movements, BlackRock, Inc. reduced its holdings by 202,944 shares, leaving it with 6,375,943 shares valued at approximately $1.34 billion. Meanwhile, Vanguard Capital Management LLC opened a new position with 4,579,274 shares worth about $960.9 million. FMR LLC decreased its stake by 2,350,642 shares, now holding 3,974,712 shares valued at $834.1 million. Vanguard Portfolio Management LLC also opened a new position, acquiring 3,449,987 shares worth roughly $723.9 million.
Insulet Corporation Stock Up 6.0%
Shares of Insulet Corporation traded near $138.97 on Tuesday. The company, with a market cap of around $9.63 billion, has a P/E ratio of 32.4 and a forward P/E of 17.2. Its beta is 1.125, indicating moderate volatility compared to the market. The stock's 52-week range spans from a low of $138.79 to a high of $354.88, with a 50-day moving average of $165.10 and a 200-day moving average of $256.42. Insulet has a current ratio of 2.49 and a debt-to-equity ratio of 77.84.
$PODD price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its recent earnings report, Insulet Corporation posted revenue of $2.90 billion, reflecting a growth rate of 33.9%. The company's net margin stood at 10.4%, with a return on equity of 23%. Earnings per share (EPS) were reported at $4.29. The next earnings announcement is expected on August 6, 2026.
Insider Buying and Selling at Insulet Corporation
Recent insider activity at Insulet Corporation saw Luciana Borio selling 418 shares at an average price of $143.27 on June 3, 2026. On the same day, Timothy Stonesifer and Elizabeth Weatherman each purchased shares, with Stonesifer buying 2,790 shares at $143.51 and Weatherman acquiring 3,450 shares at $144.20. Earlier, on May 20, 2026, insiders including Luciana Borio, Timothy Scannell, and Robert Luther Huffines each bought 1,660 shares, though no price was specified.
About Insulet Corporation
Insulet Corporation, headquartered in Acton, Massachusetts, specializes in the development and sale of innovative insulin delivery systems. Its flagship products, the Omnipod platform, include the Omnipod 5 automated insulin delivery system and the Omnipod DASH insulin management system. These devices use Bluetooth communication to integrate with glucose monitors. The company also collaborates with Amgen to supply pods for the Neulasta Onpro kit. Insulet, led by CEO Ashley A. McEvoy, employs around 5,400 people.
Bottom Line
Deutsche Bank's reaffirmation of its buy rating on Insulet Corporation, with a $190 price target, highlights ongoing confidence in the company's growth potential. Investors often track such analyst ratings for insights into future stock performance. It's important to remember that these ratings are based on past data and do not necessarily predict future outcomes.
Get Insulet Corporation alerts
New 13F filings, insider trades, and analyst moves on $PODD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.